28.11.2012 Views

best practice for the management of lymphoedema ... - EWMA

best practice for the management of lymphoedema ... - EWMA

best practice for the management of lymphoedema ... - EWMA

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Introduction<br />

Lymphoedema is a progressive chronic<br />

condition that affects a significant number<br />

<strong>of</strong> people and can have deleterious effects on<br />

patients' physical and psychosocial health.<br />

Even though it may be greatly ameliorated by<br />

appropriate <strong>management</strong>, many patients<br />

receive inadequate treatment, are unaware<br />

that treatment is available or do not know<br />

where to seek help. Several recent systematic<br />

reviews have highlighted <strong>the</strong> distinct lack <strong>of</strong><br />

evidence <strong>for</strong> <strong>the</strong> optimal <strong>management</strong> <strong>of</strong><br />

<strong>lymphoedema</strong> 1-3 . By presenting a model <strong>for</strong><br />

<strong>best</strong> <strong>practice</strong> in <strong>lymphoedema</strong> in adults, this<br />

document aims to raise <strong>the</strong> pr<strong>of</strong>ile <strong>of</strong> <strong>the</strong><br />

condition and improve <strong>the</strong> care that patients<br />

receive.<br />

ABOUT THIS DOCUMENT<br />

The guidance provided here was derived<br />

from a UK national consensus on standards<br />

<strong>of</strong> <strong>practice</strong> <strong>for</strong> people who are at risk <strong>of</strong> or<br />

who have <strong>lymphoedema</strong> (Box 1). The<br />

consensus process (Box 2) was launched in<br />

2002 and was driven by <strong>the</strong> Lymphoedema<br />

Framework with input from national patient<br />

support groups, patients with<br />

<strong>lymphoedema</strong>, national pr<strong>of</strong>essional<br />

<strong>lymphoedema</strong> groups, clinical experts and<br />

industry (Appendix 1). Production <strong>of</strong> this<br />

document included review by an<br />

international panel <strong>of</strong> experts and<br />

endorsement by key national <strong>lymphoedema</strong><br />

organisations.<br />

The recommendations resulting from <strong>the</strong><br />

consensus approach are included where<br />

relevant. Each recommendation has been<br />

classified according to <strong>the</strong> UK NHS Health<br />

BOX 2 Consensus process<br />

The recommendations made in this document<br />

are <strong>the</strong> result <strong>of</strong> a highly rigorous, systematic<br />

process based on an explicit methodology <strong>of</strong><br />

consultation and consensus4 that involved:<br />

■ developing multidisciplinary, nationally<br />

representative groups<br />

■ identifying and critically appraising <strong>the</strong> <strong>best</strong><br />

available in<strong>for</strong>mation<br />

■ linking recommendations to supporting<br />

evidence<br />

Technology Assessment model <strong>for</strong> guideline<br />

development (Box 3) 4 .<br />

This document will be reviewed and<br />

updated after five years. Key references<br />

have been included; a complete list <strong>of</strong> <strong>the</strong><br />

references used in <strong>the</strong> preparation <strong>of</strong> <strong>the</strong><br />

text can be found at: www.lf.cricp.org.<br />

ABBREVIATIONS<br />

ABPI: ankle-brachial pressure index<br />

IPC: intermittent pneumatic compression<br />

MLD: manual lymphatic drainage<br />

MLLB: multi-layer inelastic <strong>lymphoedema</strong><br />

bandaging<br />

SLD: simple lymphatic drainage (self massage)<br />

TBPI: toe-brachial pressure index<br />

Standard 1: Identification <strong>of</strong> people at<br />

risk <strong>of</strong> or with <strong>lymphoedema</strong><br />

Systems to identify people at risk <strong>of</strong> or<br />

with <strong>lymphoedema</strong>, regardless <strong>of</strong> cause,<br />

will be implemented and monitored to<br />

ensure that patients receive high quality<br />

education and lifelong care<br />

Standard 2: Empowerment <strong>of</strong> people at<br />

risk <strong>of</strong> or with <strong>lymphoedema</strong><br />

Individual plans <strong>of</strong> care that foster self<strong>management</strong><br />

will be developed in<br />

partnership with patients at risk <strong>of</strong> or<br />

with <strong>lymphoedema</strong> (involving relatives<br />

and carers where appropriate), in an<br />

agreed <strong>for</strong>mat and language<br />

Standard 3: Provision <strong>of</strong> <strong>lymphoedema</strong><br />

services that deliver high quality clinical<br />

care that is subject to continuous<br />

improvement and integrates<br />

community, hospital and hospice based<br />

services<br />

All people at risk <strong>of</strong> or with<br />

<strong>lymphoedema</strong> will have access to trained<br />

healthcare pr<strong>of</strong>essionals, including<br />

<strong>lymphoedema</strong> specialists, who will work<br />

to agreed standards <strong>for</strong> comprehensive<br />

ongoing assessment, planning,<br />

education, advice, treatment and<br />

monitoring. Care will be <strong>of</strong> a high<br />

standard and subject to continuous<br />

quality improvement<br />

INTRODUCTION<br />

BOX 3 Classification <strong>of</strong><br />

recommendations4 A<br />

Clear research<br />

evidence<br />

B<br />

Limited supporting<br />

research evidence<br />

C<br />

Experienced common<br />

sense judgement<br />

BOX 1 Standards <strong>of</strong> <strong>practice</strong> <strong>for</strong> <strong>lymphoedema</strong> services, adapted from 5<br />

Standard 4: Provision <strong>of</strong> high quality<br />

clinical care <strong>for</strong> people with<br />

cellulitis/erysipelas<br />

Agreed protocols <strong>for</strong> <strong>the</strong> rapid and<br />

effective treatment <strong>of</strong> cellulitis/<br />

erysipelas, including prevention <strong>of</strong><br />

recurrent episodes, will be<br />

implemented and monitored by<br />

healthcare pr<strong>of</strong>essionals who have<br />

completed recognised training in this<br />

subject<br />

Standard 5: Provision <strong>of</strong> compression<br />

garments <strong>for</strong> people with<br />

<strong>lymphoedema</strong><br />

Agreed protocols <strong>for</strong> assessment <strong>for</strong><br />

and <strong>the</strong> provision <strong>of</strong> compression<br />

garments <strong>for</strong> people with<br />

<strong>lymphoedema</strong>, or where warranted,<br />

those at risk <strong>of</strong> <strong>lymphoedema</strong>, will be<br />

implemented and monitored<br />

Standard 6: Provision <strong>of</strong> multi-agency<br />

health and social care<br />

Following comprehensive assessment,<br />

any patient at risk <strong>of</strong> or with<br />

<strong>lymphoedema</strong> who requires multiagency<br />

support will have access to and<br />

receive care appropriate to <strong>the</strong>ir needs<br />

from health and social services<br />

BEST PRACTICE FOR THE MANAGEMENT OF LYMPHOEDEMA 1

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!